CRISPR Editing of BCL11A Enhancer for Fetal Hemoglobin Induction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemoglobinopathies such as sickle cell disease and beta-thalassemia are inadequate, with gene therapy and hematopoietic stem cell transplantation carrying risks and limitations, necessitating improved methods for managing these conditions.
Innovation Solution
Genome editing systems using CRISPR-mediated methods to alter gamma-globin genes and increase expression of fetal hemoglobin by targeting specific nucleotide regions and motifs, such as the 13 nt target region and GATA1 binding motif in the BCL11A gene, to enhance transcriptional activity and induce fetal hemoglobin production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy or hematopoietic stem cell transplantation is used to treat hemoglobinopathies, then treatment effectiveness is improved, but safety risks and procedural complexity increase
Solution Approach 1:
The patient's own hematopoietic stem cells are harvested, genetically modified ex vivo to correct the hemoglobinopathy mutation, and then retransferred back to the patient. This autologous approach eliminates the need for immunosuppression and graft-versus-host disease prevention required in allogeneic transplants, significantly reducing safety risks while maintaining treatment effectiveness.
Solution Approach 2:
The patent uses an ex vivo culture system as an intermediary between the patient's stem cells and the final transplantation. The stem cells are modified outside the body in a controlled environment, allowing for thorough quality control and safety verification before reinfusion, thereby reducing the harmful effects associated with in vivo gene therapy approaches.
2Object-affected harmful factors
If genome editing is performed ex vivo on hematopoietic stem cells, then safety is improved by avoiding in vivo modifications, but device complexity and procedural steps increase
Solution Approach 1:
The treatment process is divided into distinct sequential steps: stem cell harvesting, ex vivo expansion, genetic modification, quality control testing, and reinfusion. This segmentation allows each step to be optimized and controlled independently, managing overall procedural complexity while enabling safe ex vivo editing that avoids the hazards of in vivo modification.
Solution Approach 2:
All genetic modifications and safety validations are performed in advance during the ex vivo culture phase before the modified cells are reinfused into the patient. This preliminary action ensures that only safely modified cells enter the patient's body, eliminating the uncontrolled effects of in vivo editing while the standardized protocols keep procedural complexity manageable.
3Object-generated harmful factors
If fetal hemoglobin expression is increased to treat hemoglobinopathies, then disease symptoms are alleviated, but the underlying genetic mutation remains unchanged
Solution Approach 1:
Instead of attempting to correct the mutated beta-globin gene directly, the patent inverts the approach by targeting the gamma-globin genes that are normally silenced in adults. By using CRISPR-Cas9 to delete the BCL11A enhancer element that represses gamma-globin expression, the therapy activates fetal hemoglobin production as an alternative to the defective adult hemoglobin, thereby alleviating symptoms while the genetic inversion strategy provides a more reliable long-term solution than symptomatic management alone.
Solution Approach 2:
The patent fundamentally changes the hemoglobin composition parameter in adult patients by increasing fetal hemoglobin (HbF) levels from near-zero to therapeutically significant amounts. This parameter change addresses the root cause of hemoglobinopathies by replacing defective adult hemoglobin with functional fetal hemoglobin, providing curative potential rather than merely managing symptoms.
Data Source
AI summary
Genome editing systems, guide RNAs, and CRISPR-mediated methods are provided for altering portions of the HBG1 and HBG2 loci, portions of the erythroid specific enhancer of the BCL11A gene, or a combination thereof, in cells and increasing expression of fetal hemoglobin.